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Abstract
Background—Genome-wide association studies have identified multiple genetic variants 
associated with prostate cancer (PrCa) risk which explain a substantial proportion of familial 
relative risk. These variants can be used to stratify individuals by their risk of PrCa.
Methods—We genotyped 25 PrCa susceptibility loci in 40,414 individuals and derived a 
polygenic risk score (PRS). We estimated empirical Odds Ratios for PrCa associated with 
different risk strata defined by PRS and derived age-specific absolute risks of developing PrCa by 
PRS stratum and family history.
Results—The PrCa risk for men in the top 1% of the PRS distribution was 30.6 (95% CI 16.4–
57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI 3.2–5.5) fold compared with the 
median risk. The absolute risk of PrCa by age 85 was 65.8% for a man with family history in the 
top 1% of the PRS distribution, compared with 3.7% for a man in the bottom 1%. The PRS was 
only weakly correlated with serum PSA level (correlation=0.09).
Conclusions—Risk profiling can identify men at substantially increased or reduced risk of 
PrCa. The effect size, measured by OR per unit PRS, was higher in men at younger ages and in 
men with family history of PrCa. Incorporating additional newly identified loci into a PRS should 
improve the predictive value of risk profiles.
Impact—We demonstrate that the risk profiling based on SNPs can identify men at substantially 
increased or reduced risk that could have useful implications for targeted prevention and screening 
programs.
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Introduction
Genome-wide association studies (GWAS) have identified multiple common genetic 
variants associated with prostate cancer (PrCa) risk. The risks associated with such variants 
are generally modest, but in combination their effects may be substantial, and may provide 
the basis of targeted prevention (1). However, since the risks associated with these variants 
are modest, large studies are required to estimate their risks precisely. To facilitate this 
estimation, we genotyped 25 PrCa susceptibility SNPs in studies from the PRACTICAL 
consortium. PRACTICAL is an international PrCa consortium that includes more than 78 
studies, including men of European, Asian or African ancestry, and has a combined dataset 
of over 130,000 samples (http://practical.ccge.medschl.cam.ac.uk/). In the current analysis, 
we utilised data from 31,833 cases and controls from 24 studies in PRACTICAL and 8,581 
samples from replication stage of a GWAS (“GWAS stage 3”). Sixteen out of the twenty 
five SNPs that we used in this study were identified through studies that included 
PRACTICAL (2–4) and nine SNPs were identified by other GWAS (5–10).
Materials and Methods
Samples
The current analysis was restricted to individuals of European ancestry, based on self-
reported ethnicity, and thus we excluded samples with non-European ancestry. Data were 
contributed from 25 studies in PRACTICAL and GWAS stage 3. Twenty five SNPs were 
genotyped specifically for this analysis in 31,833 cases and controls in PRACTICAL phase 
III, unless the genotype data were already available. We also included four studies from the 
GWAS stage 3 conducted in the United Kingdom and Australia, comprising a further 8,581 
cases and controls (11). In this replication stage 1,536 SNPs were genotyped, including the 
25 susceptibility SNPs analysed here. These two datasets were combined to give a total of 
40,414 samples (20,288 cases and 20,126 controls). Three studies (MCCS, PFCS and 
UKGPCS) that were included in the GWAS stage 3 also contributed genotyping of 
additional samples for PRACTICAL phase III (Table 1, Supplementary Table 1 and 
Supplementary Notes). Studies provided a minimum core dataset that included disease 
status, age at diagnosis/observation and ethnicity. Twenty two studies provided data on 
family history and eighteen studies provided data on Gleason score.
Where studied included more than one individual from the same family, only the index case 
was included, so that the analyses were based on unrelated men. For analyses of the 
polygenic risk score (PRS) we also excluded 5 studies (MAYO, PCFS, TASPRAC, ULM 
and UTAH) that oversampled cases with family history of PrCa. This reduced the total 
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number of samples to 34,986 (16,643 cases and 18,343 controls). All studies were approved 
by the relevant ethics committees.
Eighty Nine percent (31,150) of the samples had information on age at diagnosis (interview/
blood draw for controls). The mean age at diagnosis for the cases was 64 years, slightly 
higher than the mean age at interview/blood draw for the controls (58 years; Supplementary 
Table 2a). Family history information was available for 21,209 (60.6%) samples and among 
samples with family history information, 10.7% of controls and 18.2% of cases had a family 
history of PrCa. Before excluding studies with oversampled familial cases, these percentages 
were 12.9% and 22.6% respectively (Supplementary Table 2a and b).
Genotyping
Genotyping was performed in two experiments; these were subject to separate QC 
procedures appropriate to the platforms used, before the data were combined for statistical 
analysis. In PRACTICAL phase III, genotyping of samples from 2 studies was performed by 
Sequenom, while 22 study sites performed the 5’exonuclease assay (Taqman™) using the 
ABI Prism 7900HT sequence detection system according to the manufacturer’s instructions. 
Primers and probes were supplied directly by Applied Biosystems as Assays-By-Design™. 
Assays at all sites included at least four negative controls and 2–5% duplicates on each 384-
well plate. Quality control guidelines were followed by all the participating groups as 
previously described (4). In addition, all sites also genotyped 16 CEPH samples. We 
excluded individuals that were not typed for at least 80% of the SNPs attempted. Data on a 
given SNP for a given site were also excluded if they failed any of the following QC criteria: 
SNP call rate >95%, no deviation from Hardy-Weinberg equilibrium in controls at P<.
00001; <2% discordance between genotypes in duplicate samples and in the CEPH control 
samples. Cluster plots for SNPs that were close to failing any of the QC criteria were re-
examined centrally.
GWAS Stage 3 genotypes were generated using an Illumina Golden Gate Assay. All SNPs 
for this analysis passed the QC filters used for this experiment: call rate>95%, a minor allele 
frequency in controls of >1%, or genotype frequency in controls consistent with Hardy-
Weinberg equilibrium at p<0.00001. Duplicate concordance was 99.99% (11).
Statistical methods
We used combined data across all studies for the analysis. We assessed the association 
between each SNP and PrCa using a 1-degree-of-freedom Cochran-Armitage trend test, 
stratified by studies. Odds ratios (OR) and 95% confidence intervals (95% CI) associated 
with each genotype and cancer risk, and genotypes for pairs of SNPs, were estimated using 
unconditional logistic regression, stratified by study as a covariate. Both per-allele ORs, and 
genotype-specific ORs, were estimated. Heterogeneity in the OR estimates among studies 
was evaluated using a likelihood ratio test, by comparing with a model in which separate 
ORs were estimated for each study.
Modification of the ORs by disease aggressiveness and family history was assessed by using 
both family history (Yes vs. No) and Gleason score (<8 vs. ≥8) as binary variables. A test for 
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association between SNP genotype at a locus and Gleason score as an ordinal variable was 
also performed, using polytomous regression. Modification of the ORs by age was assessed 
using a case-only analysis, assessing the association between age and SNP genotype in the 
cases using polytomous regression. The associations between SNP genotypes and PSA level 
were assessed using linear regression, after log-transformation of PSA level to correct for 
skewness.
Contribution to Familial Risk
The contribution of the known SNPs to the familial risk of PrCa, under a multiplicative 
model, was computed using the formula:
where λ0 is the observed familial risk to first degree relatives of PrCa cases, assumed to be 2 
(12), and λk is the familial relative risk due to locus k, given by:
where Pk is the frequency of the risk allele for locus k, qk = 1 − Pk and rk is the estimated 
per-allele odds ratio (13).
To evaluate evidence for interactions between pairs of SNPs, we used a likelihood ratio test 
and evaluated the evidence for departures from a multiplicative model, by comparing 
models with and a model without the interaction term for each pair of SNPs. The interaction 
term was the product of the allele doses for the two SNPs, hence leading to a 1 degree of 
freedom test for an interaction. Based on the assumption of a log-additive model, we 
constructed a PRS from the summed genotypes weighted by the estimated per-allele log-
odds ratios for each SNP, as estimated by logistic regression as above. Thus for each 
individual j we derived:
Where:
N : Number of SNPs (25)
gij : Allele dose at SNP i (0, 1, 2) for individual j
β i : Per-allele log-odds ratio of SNP i
The missing genotypes for an individual were replaced with the mean genotype of each SNP 
separately for cases and controls. A sensitivity analysis, in which analyses were based on 
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samples with complete genotype data, gave very similar results (data not shown). We then 
standardised the PRS by dividing by the overall standard deviation of PRS in the controls.
The risk of PrCa was estimated for the percentiles of the distribution of the PRS; <1%, 1–
10%, 10–25%, 25–75% (defined here as “median risk”), 75–90%, 90–99%, >99%; and per 
standard deviation when fitted as a continuous covariate. We evaluated the fit of the 
combined risk score to a log-linear model by comparing the model with the PRS fit as a 
continuous covariate with a model in which separate parameters were estimated for 
percentiles of risk adjusted for age at diagnosis and family history, using a likelihood ratio 
test.
We used a likelihood ratio test to evaluate the evidence for interaction between PRS and age 
at diagnosis/observation, PRS and family history and also family history and age at 
diagnosis/observation by comparing models with and a model without an interaction term. 
Effect sizes by family history were compared using a case-only analysis. Analyses were 
performed using Stata 13.
The relative risk estimates were used to obtain estimates of the absolute risk of PrCa by PRS 
category and family history. Since we observed evidence for an interaction between PRS 
and age, we used both models with and without PRS × age interaction term. Absolute risks 
were constrained such that the age-specific incidences, averaged over all categories of PRS 
and family history, were consistent with the age-specific incidences of PrCa for the UK 
population for 2012 (http://ci5.iarc.fr/CI5plus) (14). The model was adjusted for age at 
diagnosis (age <55, 55–59, 60–64, 65–70 and 70+). The procedure for deriving the age-
specific incidences for each SNP profile category has been performed following the 
procedure explained by Antoniou et al. (15, 16), but adjusted to allow for competing causes 
of death.
For this purpose, we categorised PRS into seven risk groups (k=risk group 1 to 7), based on 
the percentile in the controls: <1%, 1–10%, 10–25%, 25–75%, 75–90%, 90–99% and >99%. 
We could not find any evidence for an interaction between PRS and family history of PrCa 
(P-value=0.49) and assumed that family history and PRS are independently predictive of 
PrCa risk. Under this model, the PrCa incidence  at age t for an individual in risk group 
k and family history group h (h=1 with family history, h=0 no family history) was assumed 
to follow a model of the form:  where λ0 (t) is the baseline PrCa 
incidence and  is the risk ratio in the risk group k and family history group h, 
relative to the baseline category (h=0, k=1), approximated by the odds ratio estimates from 
the logistic regression analysis. To obtain the baseline incidence, λ0 (t), we constrained the 
PrCa incidence averaged all risk groups to agree with the population age-specific PrCa 
incidences μ(t) (the incidence of PrCa at age t per 100,000 individuals in the UK (14)). The 
baseline incidence can be obtained for each age by:
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Here P0 is the probability of having no family history in the population (89.26% in the 
controls in this dataset) and p1 = 1 − p0 is the probability of having family history in the 
population (10.74% in the controls in this dataset). fk is frequency of the SNP profile risk 
group k (f1=0.01, (f2=0.09, (f3=0.15, (f4=0.5, (f5=0.15, (f6=0.09, (f7=0.01) and  is the 
probability of surviving PrCa by age (t) in the risk group k for samples in the family history 
group h, which can be derived from incidence rates  for ages <t using the formula 
. Since definition  for all k and h, it was possible to 
solve the above equation recursively, starting at age t=0, to obtain the baseline incidences 
and hence the age-specific PrCa incidences at age (t), , for each group. We then 
computed the absolute risk by age t, adjusting for mortality from other causes, for each risk 
group, using the formula: 
Where  is the probability of not dying from another cause of 
death by age t, based on the age-specific mortality rates μc(t). The age-specific mortality 
rates, μc(t), was estimated by using all causes incidences of death per 100,000 individuals 
for England and Wales (http://www.ons.gov.uk/ons/index.html) and the PrCa death 
incidence per 100,000 individuals in UK in year 2012 (14).
Results
All 25 SNPs showed evidence of association with PrCa (P=0.02 to P=1.4×10−46), with 
effect sizes that were consistent with previous reports. The largest per-allele OR estimate 
was 1.56 (95% CI 1.44–1.68) for rs16901979 on 8q24 (Table 2). For each of the 24 
autosomal SNPs, the effect size was larger for rare homozygotes than for heterozygotes, and 
the estimates were consistent with a multiplicative (log-additive) model. There was no 
evidence for heterogeneity among studies (Table 2).
Gleason score was available for 15,107 (74.5%) of the cases used in the analyses; of these, 
2,139 had a score of 8+ and 12,968 had a score less than 8. One SNP, rs1447295, on 
chromosome 8, showed a larger effect size with increasing grade (P=0.001), while four 
SNPs (rs17021918, rs1512268, rs7127900 and rs2735839) showed a larger effect sizes with 
decreasing grade (P<0.02; Supplementary Table 3).
Thirteen of the SNPs (rs1465618, rs7679673, rs10486567, rs1447295, rs6983267, 
rs16901979, rs10993994, rs7931342, rs7127900, rs4430796, rs11649743, rs1859962 and 
rs5759167) showed a higher per-allele OR for cases with a PrCa family history than those 
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without (P<0.05), while no SNPs showed an effect in the opposite direction consistent with 
the predictions under a polygenic model (17) (Supplementary Table 3).
Data on serum PSA level were available for 3,922 controls from 6 studies. Six SNPs 
(rs1447295, rs6983267, rs1512268, rs10993994, rs7127900 and rs2735839) showed 
association with PSA concentration levels significant at P-value < 0.03. rs1447295 showed 
an association with PSA in the opposite direction of the PrCa risk association but the rest of 
five SNPs showed an association with PSA in the same direction of the PrCa risk association 
(Supplementary Table 4).
Seven SNPs (rs1465618, rs12621278, rs10993994, rs7127900, rs1859962, rs2735839 and 
rs5945619) showed an evidence for a trend in the per-allele ORs with age; in each case the 
effect size was larger for cases diagnosed at younger ages (Supplementary Table 5).
The combined effect of all pairs of SNPs was evaluated through a logistic regression model 
that included each pair of SNPs and an interaction term. The interaction term was significant 
at P-value <0.05 level for 29 pairs (out of 300 possible pairs) compared with 15 expected by 
chance, and significant at the P-value <0.01 level for 12 pairs compared with 3 expected by 
chance. However, no pair was significant at the P-value <0.05 level after a bonferroni 
correction for the number of tests (nominal significance P-value=1.6×10−4, Supplementary 
Table 6).
Under the assumption that these 25 SNPs combined approximately multiplicatively to alter 
the risk of PrCa, we constructed a PRS for 16,643 cases and 18,343 controls based on the 
estimated per-allele ORs of 25 SNPs, standardised by the standard deviation in controls. The 
standardised PRS had a mean=0.651 (range −3.81–5.36; SD=0.98) in cases and mean=0.104 
(range −4.05–4.15; SD=1) in controls. The standardised PRS was strongly associated with 
disease risk (OR per unit PRS =1.74, 95%CI 1.70–1.78). The OR per unit increase of the 
standardised PRS declined with age from 1.76 (95% CI 1.62–1.92) in cases diagnosed at age 
less than 55 to 1.48 (95% CI 1.37–1.60) in cases diagnosed at age 70+ (P-value= 2.6×10−4, 
Supplementary Table 5).
The OR per unit increase of PRS was larger for men with PrCa family history (1.79 Vs 1.70; 
P-value= 1.8×10−4, Supplementary Table 3). We found no evidence of an interaction 
between PRS and family history (P-value=0.49) or between age at diagnosis and family 
history (P-value=0.11) but there was some evidence for an interaction between PRS and age 
at diagnosis (P-value=0.003).
There was no evidence of a difference in the OR per unit PRS according to Gleason Score 
(OR=1.75, GS<8 Vs OR=1.65, GS 8+) after adjusting for age at diagnosis and family 
history (P=0.37; Supplementary Table 3). The correlation between PSA and the PRS was 
weak, both in controls (correlation=0.09) and in cases (correlation =0.02).
When PRS was categorised by percentile, the top 1% of the population had an estimated OR 
of 30.6 (16.4–57.3) compared with the bottom 1% of the population, and an OR of 4.2 
(95%CI 3.2–5.5) compared with the median population risk (defined as the 25–75% risk 
group). The bottom 1% of the population had an estimated OR of 0.14 (95% CI 0.08–0.24) 
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compared with the median risk (Table 3). After allowing for an interaction between PRS and 
age, the OR for the top 1% of the population, relative to the median risk group, decreased 
from 5.6, for men below age <55 years, to 3.8 for men aged 70+ years (Supplementary 
Table 7 & 8).There was no difference between fit of the model with a continuous covariate 
for PRS and the model with separate parameters for percentiles of the PRS (P=0.24). In 
particular, the predicted ORs for the top 1% and the bottom 1% of the population, based on a 
log-linear model, did not differ from that observed.
To estimate the absolute risk of PrCa for different risk groups defined by the combined 
genotypes at the 25 PrCa susceptibility loci, we fitted a logistic regression model that It 
included parameters for PRS (in 7 categories) together with family history of PrCa once 
with (Supplementary Table 7) and once without a PRS × age at diagnosis interaction term 
(Table 3). We used both models (adjusted for age at diagnosis and family history) in order to 
estimate effect sizes for PRS. Then we used the UK age-specific incidences of PrCa (0 to 
85+ years) (14) to estimate age-specific absolute risks of PrCa in the general population 
after considering competing causes of death for fourteen risk groups defined by PRS and 
family history (seven PRS risk groups and two family history, see methods). Based on this 
analysis, the absolute risk of PrCa by age 85 for a man in the top 1% of the risk distribution 
with family history of PrCa was 65.8% (67.1% in a model not allowing for interaction) and 
for a man in the lowest 1% was 3.65% (3.67% in a model not allowing for interaction). The 
absolute risk for a man in the top 1% of the risk distribution with no family history of PrCa 
was 35.0% (36.1% in a model not allowing for interaction) and 1.46% (1.47% in a model 
not allowing for interaction) for someone in the lowest 1%. By comparison, the estimated 
absolute risk for a man in the 25–75% category was 10.2% in the absence of a family history 
of PrCa, and 23.7% for a man with family history (Figure 1 & 2, Supplementary Figure 1 & 
2).
Discussion
These results demonstrate that risk profiling based on SNPs can identify men at substantially 
increased or reduced risk of PrCa. We derived a PRS based on a sum of SNP genotypes, 
weighted by their per-allele log ORs. The estimated ORs for the highest and lowest 1% of 
the population (4.2 and 0.14, respectively) were consistent with those predicted under a 
simple polygenic model in which the log OR increases linearly with the PRS. We also 
showed that the effect size, measured by OR per unit PRS, was higher at younger ages. As 
expected, the majority of loci, and the PRS, showed a stronger effect for familial cases. In a 
logistic regression model, both PRS and family history were independently associated with 
PrCa risk. The OR due to family history was attenuated after adjustment for the PRS (from 
2.63 to 2.50), as expected given that family history is, at least in part, a reflection of genetic 
susceptibility. However, the degree of attenuation (5% on a log-scale) was markedly less 
than 18%, the estimated contribution of these 25 loci to the familial risk of PrCa estimated 
based on their ORs and allele frequencies in this study (see methods). The reason for this 
difference is unclear but might reflect interactions between the known susceptibility loci 
summarised in the PRS and other factors influencing family history.
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In order to investigate the added value of PRS, once we estimated the absolute risk for 
individuals with family history without fitting their PRS information and then repeated the 
same procedure after adding their PRS information. The absolute risk of PrCa for a man at 
age 85 with family history was estimated to be 26.5% when PRS information was ignored. 
When we incorporated PRS information, a man at age 85,depend on his PRS risk group, 
could have an absolute risk ranging from 3.67% (if a man is in the bottom 1% of the risk 
distribution) to 67.1% (if a man is in the top 1% of the risk distribution, Supplementary 
Figure 1 and 3). These observations indicate that family history and the PRS independently 
influence risk and can be combined to provide stronger discrimination.
Chatterjee et al. derived theoretical estimates for the predictive performance of polygenic 
models for ten complex traits or common diseases, including PrCa, using published 
estimates for individual SNPs (18). They estimated that ~7% of the population will be at 
two-fold risk or greater for PrCa. We estimated, empirically, that the (average) risk to men 
in the 90–99% category of the PRS was 2.41 fold, relative to the population median, or 
approximately 2 fold relative to the population mean. However, this is an average risk over 
the 90–99% category, so that the percentile of the PRS at which the risk exceeds 2 fold will 
be >90%. Based on the estimated log(OR) per standardised PRS, approximately 6% of men 
will have a risk of greater than twofold, very close to the estimate of Chatterjee et al (18).
These results show that genetic risk profiling using SNPs could be useful in defining men at 
high risk for the disease for targeted prevention and screening programs. The benefits of 
screening, relative to the costs, will be most favourable among men at higher risk. If, for 
example, the benefit-cost ratio is favourable for screening men at a greater than two-fold 
risk, the PRS provides an effective method for identifying such men.
While these analyses demonstrate the value of SNPs for risk prediction, a risk model could 
be improved in various ways. The analyses presented here are based on the 25 loci first 
identified to be associated with PrCa. Recently, however, additional loci have been 
identified (13, 19) and more than 100 common susceptibility loci are now known. In total, 
these loci increase the estimated proportion of the familial risk to 33% (19). Incorporating 
all known loci into a PRS should improve the predictive value of risk profiles.
Additionally, the analyses presented here consider family history as a binary (yes/no) 
covariate. It is known that the risk of PrCa is dependent on both the number of affected 
relatives and their ages. MacInnis et al. (12, 20) have shown using segregation analysis that 
the familial aggregation of PrCa can be modelled as the combined effect of a recessive allele 
and a polygenic component, and that the polygenic component can be further partitioned 
into a component due to measured SNPs and an unmeasured component. This approach 
should provide more powerful prediction, particularly in families with multiple cases of the 
disease. Finally, it is known that serum or urine PSA level is associated with PrCa risk, with 
the association persisting for several decades. Although some of the risks SNPs are also 
related to PSA level in the expected direction, the PSA level is only weakly correlated with 
PRS, indicating that incorporating PSA level and potentially other markers such as MSMB 
(21) into a risk algorithm should further improve the discrimination (22).
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The absence of clear differences in the relative risk associated with SNPs by disease 
aggressiveness, even in this very large study, is striking. We did not find any convincing 
evidence for differences in the predictive values of the PRS by disease aggressiveness. The 
effect size was higher for less aggressive disease, but the difference was still small (1.75 vs. 
1.65). This result is in contrast to the clear differences in SNP associations by disease 
pathology seen in other diseases, for example in breast and ovarian cancer, and indicates that 
aggressive and non-aggressive disease, at least as measured by Gleason score, share these 
genetic risk factors as a common aetiology.
Analysis of pairwise combinations of SNPs did not identify any clear examples of departure 
from a multiplicative model, after adjusting for multiple testing. We did, however, find an 
excess of interactions at the P<0.01 level over the number that would be expected by 
chance. This suggests that interactions on this scale likely to exist, but their effect sizes are 
small and that very large sample sizes, exemplified by this collaborative study, will be 
required to identify and characterise them. If such interactions could be identified reliably, 
they may improve the predictive value of the risk profiling, and also provide insights into 
the biological interactions between the underlying risk variants.
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Figure 1. 
Absolute risk of PrCa by age in men with family history.
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Figure 2. 
Absolute risk of PrCa by age in men with no family history.
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Table 1
Total numbers of cases and controls used in the analyses
Study Controlsa Casesa Totala
GWAS Stage 3 4,076 4,505 8,581
PRACTICAL 16,050 15,783 31,833
Total 20,126 20,288 40,414
Totalb 18,343 16,643 34,986
aAnalyses were restricted to men of European ancestry (see text).
b
Total after excluding 5 studies that oversampled cases with family history.
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Table 3
Odds ratios for PrCa by percentile of the PRS and family history.
Percentiles ORa,b ORa,c
PRS Group
< 1% 1 (baseline) 0.14 (0.08–0.24)
1–10% 2.98 (1.66–5.35) 0.41 (0.36–0.47)
10–25% 4.59 (2.58–8.17) 0.63 (0.57–0.70)
25–75% 7.23 (4.08–12.80) 1 (baseline)
75–90% 12.13 (6.83–21.54) 1.68 (1.54–1.83)
90–99% 16.70 (9.38–29.72) 2.31 (2.09–2.56)
>= 99% 30.63 (16.36–57.34) 4.24 (3.24–5.53)
Family History 2.52 (2.29–2.78) 2.52 (2.29–2.78)
aORsobtained by fitting PRS group, family history and age at diagnosis jointly.
bORs compared to men in the 1st percentile as baseline.
cORs compared to men in the 25th–75th percentile as baseline.
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